First cancer vaccine test for advanced lung, ovarian, or prostate cancer
Part of Cancer, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This Phase 1 study tests OVM-200, a new cancer vaccine, to see how it is tolerated and how it affects the immune system in people with advanced NSCLC, ovarian cancer, or prostate cancer. You may be eligible if your cancer has already had approved treatment(s) and no further standard options are planned within the first two months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed metastatic or locally advanced cancer: non-small cell lung cancer, ovarian cancer, or prostate cancer
- You’ve already had at least one approved cancer treatment, and either options are used up or you’re stable during a planned treatment break (or prostate cancer is stable on hormone-blocking therapy)
- You’re not currently receiving active cancer treatment (except supportive care; prostate hormone-blocking may continue) and likely won’t need new approved anti-cancer treatment before the Week 8 check
- Your scans show at least one measurable spot to track for NSCLC, using CT or MRI
- You’re between 18 and 75 years old, with good enough energy/activity level and expected survival of at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine called CryptiVax-1001 for people with advanced ovarian cancer who have finished first-line chemotherapy and are in remission, as maintenance therapy. The goal is to see if the vaccine can help keep the cancer from coming back.
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
This study tests two new experimental drugs (XmAb541 and XmAb808) designed to fight advanced ovarian cancer by activating your immune system. You'll be closely monitored to see how safe the drugs are and how your body tolerates them.
This trial tests a new drug (DC05F01) for people with ovarian cancer that has come back after platinum treatment, or for those with other advanced solid tumors that haven't responded to standard therapies. It aims to see if the drug is safe and effective.
This trial tests a combination treatment for advanced ovarian cancer that hasn't been treated before. It combines chemotherapy, a personalized vaccine made from your own immune cells, and a drug called pembrolizumab to help your immune system fight the cancer.
This trial tests a personalized vaccine (NeoOVSV) made from your tumor’s unique markers (neoantigens). It’s for women with Stage II or III epithelial ovarian cancer who had successful surgery to remove all visible cancer. The goal is to see if the vaccine is safe and helps your immune system fight any remaining cancer cells.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.